Ares set to make offer for whole of Stallergenes

Ares Life Sciences, a Switzerland-based healthcare investment firm, must launch a takeover bid for Stallergenes, after acquiring 45.86% of the French allergy-specialist from Wendel, a French investment firm, for €59 per share. Wendel will receive around €358.8 million from Ares and is expected to declare a capital gain of around €300 million. Ares has told Stallergenes that it does not foresee any change within Stallergenes' jobs, salary or human resources policies.

Ares Life Sciences, a Switzerland-based healthcare investment firm, must launch a takeover bid for Stallergenes, after acquiring 45.86% of the French allergy-specialist from Wendel, a French investment firm, for €59 per share. Wendel will receive around €358.8 million from Ares and is expected to declare a capital gain of around €300 million. Ares has told Stallergenes that it does not foresee any change within Stallergenes' jobs, salary or human resources policies.

Under French law, Ares must file a tender offer for all the remaining outstanding shares of Stallergenes - held either...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By 

François Roger believes fixing inefficiencies is more important than playing with pricing.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By 

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapeutic Category

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.